Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...

Libtayo was first approved in 2018, several years after Bristol-Myers Squibb and Merck & Co began to gain market share in many oncology indications with their rival PD-1 drugs Opdivo (nivolumab ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a ...

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation. Given the current uncertainties and risks, I rate ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment ...